HC Wainwright & Co. Downgrades Paratek Pharmaceuticals to Neutral, Announces $2.15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce downgraded Paratek Pharmaceuticals (NASDAQ:PRTK) from Buy to Neutral and announced a $2.15 price target.
June 07, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Paratek Pharmaceuticals downgraded to Neutral by HC Wainwright & Co. with a $2.15 price target.
The downgrade from Buy to Neutral by HC Wainwright & Co. analyst Ed Arce indicates a less optimistic outlook for Paratek Pharmaceuticals. This could lead to a negative short-term impact on the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100